The skeleton is the most common site of colonization by metastatic cancers. Zoledronic acid (ZA) has been shown to be effective for the treatment of bone metastases regardless of whether the bone lesions are osteolytic or osteoblastic. Biochemical markers of bone turnover may be useful tools to quantify the degree of bone remodeling in the presence of bone metastases. The aim of this work was to establish the correlation between tumor dispersión (bioluminescence) and biochemical markers of bone turnover in two osteolytic and osteoblastic metastasis models in mice.
They found that the best biomarkers for the diagnosis of both osteolytic and osteoblastic metastasis are formation markers, especially BGP.Moreover, these markers can be useful in the follow-up of the treatment with ZA in both types of metastasis.
Transl Oncol. 2017 Apr;10(2):255-261. doi: 10.1016/j.tranon.2016.12.001.
Martín-Fernández M, Valencia K, Zandueta C, Ormazábal C, Martínez-Canarias S, Lecanda F, de la Piedra C.